Express Scripts Holding Co. (NASDAQ:ESRX) shares were down 4.3% during mid-day trading on Thursday . The stock traded as low as $72.99 and last traded at $73.02, with a volume of 6,163,307 shares changing hands. The stock had previously closed at $76.34.

Several research analysts recently issued reports on ESRX shares. Bank of America Corp. reaffirmed a “neutral” rating and set a $82.00 target price on shares of Express Scripts Holding in a research report on Tuesday, June 7th. Zacks Investment Research raised Express Scripts Holding from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research report on Tuesday, June 7th. Cowen and Company reaffirmed a “positive” rating and set a $83.00 target price on shares of Express Scripts Holding in a research report on Wednesday, June 15th. Jefferies Group restated a “buy” rating on shares of Express Scripts Holding in a research note on Monday, July 4th. Finally, Credit Suisse Group AG restated a “buy” rating on shares of Express Scripts Holding in a research note on Monday, June 27th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. Express Scripts Holding presently has a consensus rating of “Hold” and an average price target of $81.26.

The firm’s 50 day moving average is $77.22 and its 200 day moving average is $73.32. The company has a market capitalization of $45.21 billion and a P/E ratio of 17.73.

Express Scripts Holding (NASDAQ:ESRX) last announced its earnings results on Monday, July 25th. The company reported $1.57 EPS for the quarter, hitting the Zacks’ consensus estimate of $1.57. The company earned $25.20 billion during the quarter, compared to the consensus estimate of $25.42 billion. Express Scripts Holding’s revenue for the quarter was down .9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.44 earnings per share. On average, equities analysts predict that Express Scripts Holding Co. will post $6.38 earnings per share for the current fiscal year.

A number of institutional investors recently made changes to their positions in ESRX. Palladium Partners LLC boosted its position in shares of Express Scripts Holding by 1.5% in the fourth quarter. Palladium Partners LLC now owns 20,031 shares of the company’s stock worth $1,751,000 after buying an additional 304 shares in the last quarter. Parsons Capital Management Inc. RI boosted its position in shares of Express Scripts Holding by 1.0% in the fourth quarter. Parsons Capital Management Inc. RI now owns 33,337 shares of the company’s stock worth $2,914,000 after buying an additional 345 shares in the last quarter. TrimTabs Asset Management LLC boosted its position in shares of Express Scripts Holding by 1.9% in the fourth quarter. TrimTabs Asset Management LLC now owns 25,886 shares of the company’s stock worth $2,263,000 after buying an additional 483 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Express Scripts Holding by 4.2% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 12,280 shares of the company’s stock worth $1,073,000 after buying an additional 500 shares in the last quarter. Finally, Suntrust Banks Inc. boosted its position in shares of Express Scripts Holding by 0.4% in the fourth quarter. Suntrust Banks Inc. now owns 185,177 shares of the company’s stock worth $16,184,000 after buying an additional 803 shares in the last quarter.

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.